Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
===================================================================================================================================================================================================================

* Diwakar Davar
* Ludimila Cavalcante
* Nehal Lakhani
* Justin Moser
* Michael Millward
* Meredith McKean
* Mark Voskoboynik
* Rachel E Sanborn
* Jaspreet S Grewal
* Ajita Narayan
* Amita Patnaik
* Justin F Gainor
* Mario Sznol
* Amanda Enstrom
* Lori Blanchfield
* Heidi LeBlanc
* Heather Thomas
* Michael J Chisamore
* Stanford L Peng
* Allison Naumovski